×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ANAB – anaptysbio, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ANAB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/19
12:17 pm
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at JPMorgan Chase & Co. from $66.00 to $36.00. They now have an "overweight" rating on the stock.
Low
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at JPMorgan Chase & Co. from $66.00 to $36.00. They now have an "overweight" rating on the stock.
12/18
12:21 pm
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at Truist Financial Co. from $30.00 to $20.00. They now have a "hold" rating on the stock.
Medium
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at Truist Financial Co. from $30.00 to $20.00. They now have a "hold" rating on the stock.
12/12
02:39 pm
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at Wells Fargo & Company from $56.00 to $40.00. They now have an "overweight" rating on the stock.
Low
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at Wells Fargo & Company from $56.00 to $40.00. They now have an "overweight" rating on the stock.
12/12
10:49 am
anab
AnaptysBio Stock Down as Eczema Study Fails to Meet Goals [Yahoo! Finance]
Neutral
Report
AnaptysBio Stock Down as Eczema Study Fails to Meet Goals [Yahoo! Finance]
12/12
10:42 am
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at Guggenheim from $90.00 to $36.00. They now have a "buy" rating on the stock.
Medium
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at Guggenheim from $90.00 to $36.00. They now have a "buy" rating on the stock.
12/11
06:20 pm
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $40.00 price target on the stock, down previously from $42.00.
Medium
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $40.00 price target on the stock, down previously from $42.00.
12/11
02:19 pm
anab
AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data [Yahoo! Finance]
Medium
Report
AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data [Yahoo! Finance]
12/11
12:25 pm
anab
AnaptysBio, Inc. (NASDAQ: ANAB) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating. They now have a $19.00 price target on the stock, down previously from $52.00.
Medium
Report
AnaptysBio, Inc. (NASDAQ: ANAB) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating. They now have a $19.00 price target on the stock, down previously from $52.00.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/18
04:30 pm
anab
Form SCHEDULE 13G ANAPTYSBIO, INC Filed by: Fairmount Funds Management LLC
Low
Report
Form SCHEDULE 13G ANAPTYSBIO, INC Filed by: Fairmount Funds Management LLC
12/11
04:06 pm
anab
Form 8-K ANAPTYSBIO, INC For: Dec 11
Medium
Report
Form 8-K ANAPTYSBIO, INC For: Dec 11
12/3
04:36 pm
anab
Form 4 ANAPTYSBIO, INC For: Nov 29 Filed by: RENTON HOLLINGS
Medium
Report
Form 4 ANAPTYSBIO, INC For: Nov 29 Filed by: RENTON HOLLINGS
11/29
01:30 pm
anab
Form 144 ANAPTYSBIO, INC Filed by: RENTON HOLLINGS
Neutral
Report
Form 144 ANAPTYSBIO, INC Filed by: RENTON HOLLINGS
11/14
04:00 pm
anab
Form SC 13G/A ANAPTYSBIO, INC Filed by: TANG CAPITAL MANAGEMENT LLC
Medium
Report
Form SC 13G/A ANAPTYSBIO, INC Filed by: TANG CAPITAL MANAGEMENT LLC
11/14
09:25 am
anab
Form SC 13G/A ANAPTYSBIO, INC Filed by: Deep Track Capital, LP
Low
Report
Form SC 13G/A ANAPTYSBIO, INC Filed by: Deep Track Capital, LP
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/2
Form 10-K ANAPTYSBIO, INC For: Dec 31
18.7%
6/21 AnaptysBio Inc (NASDAQ: ANAB) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. 11.8%
12/10 Form SC 13G/A ANAPTYSBIO, INC Filed by: FMR LLC 8.2%
10/1 Investors Yawn As Biotech Puts Up Positive Test Results — For 2 Patients [Investor's Business Daily] 8.1%
11/22 Form SC 13G ANAPTYSBIO, INC Filed by: TANG CAPITAL PARTNERS LP 7.8%
3/3 AnaptysBio Inc (NASDAQ: ANAB) had its price target lowered by analysts at SunTrust Banks, Inc. from $15.00 to $14.00. They now have a "hold" rating on the stock. 6.3%
5/1 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB 5.4%
4/17 Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against of AnaptysBio, Inc. (ANAB) 5.2%
4/8 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTI Surgical, AnaptysBio, Hanmi Financial, and HF Foods Group and Encourages Investors to Contact the Firm 5.2%
4/13 CLASS ACTION UPDATE for ANAB, VMW and ZM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders 5.0%
6/21 AnaptysBio Inc (NASDAQ: ANAB) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. 11.8%
12/10 Form SC 13G/A ANAPTYSBIO, INC Filed by: FMR LLC 8.2%
10/1 Investors Yawn As Biotech Puts Up Positive Test Results — For 2 Patients [Investor's Business Daily] 8.1%
11/22 Form SC 13G ANAPTYSBIO, INC Filed by: TANG CAPITAL PARTNERS LP 7.8%
3/3 AnaptysBio Inc (NASDAQ: ANAB) had its price target lowered by analysts at SunTrust Banks, Inc. from $15.00 to $14.00. They now have a "hold" rating on the stock. 6.3%
5/1 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AnaptysBio, Inc. - ANAB 5.4%
4/17 Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against of AnaptysBio, Inc. (ANAB) 5.2%
4/8 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against RTI Surgical, AnaptysBio, Hanmi Financial, and HF Foods Group and Encourages Investors to Contact the Firm 5.2%
4/13 CLASS ACTION UPDATE for ANAB, VMW and ZM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders 5.0%
TOP News Decliners
8/19
Form 8-K ANAPTYSBIO, INC For: Aug 16
-13.6%
9/30 Form 8-K ANAPTYSBIO, INC For: Sep 30 -11.8%
6/24 AnaptysBio Inc (NASDAQ: ANAB) had its "buy" rating re-affirmed by analysts at SunTrust Banks, Inc.. -11.4%
6/21 AnaptysBio Inc (NASDAQ: ANAB) was downgraded by analysts at Credit Suisse Group AG from an "outperform" rating to a "neutral" rating. -8.9%
8/10 AnaptysBio Prepares for a Potential Gear Shift [The Motley Fool] -7.8%
3/10 Form 4 ANAPTYSBIO, INC For: Mar 10 Filed by: Suria Hamza -7.2%
2/12 Form SC 13G/A ANAPTYSBIO, INC Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C. -7.0%
9/25 Form 8-K ANAPTYSBIO, INC For: Sep 24 -6.8%
3/31 ANAPTYSBIO SHAREHOLDER ALERT By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against AnaptysBio, Inc. - ANAB -5.9%
3/27 INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against AnaptysBio, Inc. and Encourages Investors with Losses to Contact the Firm -5.6%
9/30 Form 8-K ANAPTYSBIO, INC For: Sep 30 -11.8%
6/24 AnaptysBio Inc (NASDAQ: ANAB) had its "buy" rating re-affirmed by analysts at SunTrust Banks, Inc.. -11.4%
6/21 AnaptysBio Inc (NASDAQ: ANAB) was downgraded by analysts at Credit Suisse Group AG from an "outperform" rating to a "neutral" rating. -8.9%
8/10 AnaptysBio Prepares for a Potential Gear Shift [The Motley Fool] -7.8%
3/10 Form 4 ANAPTYSBIO, INC For: Mar 10 Filed by: Suria Hamza -7.2%
2/12 Form SC 13G/A ANAPTYSBIO, INC Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C. -7.0%
9/25 Form 8-K ANAPTYSBIO, INC For: Sep 24 -6.8%
3/31 ANAPTYSBIO SHAREHOLDER ALERT By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against AnaptysBio, Inc. - ANAB -5.9%
3/27 INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against AnaptysBio, Inc. and Encourages Investors with Losses to Contact the Firm -5.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: